The French Society of Pharmacology: "Primum non nocere (first, do no harm) was sacrificed here, with dramatic consequences." This retraction emphasizes the vital importance of proper clinical trials and research ethics.

This paper was a "cornerstone" that led to millions taking hydroxychloroquine unnecessarily. Later, larger trials showed the drug had no benefit for COVID-19 patients.

Join millions who have switched to Grok.

📊 Key issues leading to retraction:. Ethical concerns about patient recruitment.Questions about informed consent.Methodological problems raised by 3 co-authors.Conflicts in PCR test interpretation between research centres.

The infamous 2020 paper that sparked widespread use of hydroxychloroquine for COVID-19 has been officially retracted. Full story: #ScienceIntegrity

RT @essayasmimviu: obcecada na minha aluna do 7º ano que organizou uma tabela para avaliar os 3 meninos que ela gosta por: nível de beleza,….

Next steps:. > Understanding mechanisms behind IFIT3 overexpression.> Potential development of new antiviral therapies.> Applications beyond COVID-19 (dengue, hepatitis B, etc.).#BiomedicalResearch #Virology.

Why it matters:. > First proof of IFIT3's protective role beyond theory.> IFIT3 protein binds to viral RNA, blocking replication.> Protective effect observed despite close contact exposure.> Could be target for new antiviral treatments #MedicalResearch #Science.

Key findings:. > Studied 86 couples, found 6 cases of consistent resistance.> All resistant individuals were women.> IFIT3 gene highly expressed in resistant individuals.> Gene prevents viral replication inside cells #COVID19Research #Genetics.

🧬 Breakthrough: @USP_Oficial researchers identify IFIT3 gene as potential protector against #COVID19! Study of "discordant couples" (where only one partner got infected) reveals key mechanism of virus resistance. Published in @FrontiersIn.Read more:

His presentation discussed "metabolic checkpoints for the treatment of autoimmune diseases and cancer" ⬇️⬇️⬇️

Recently we hosted the PhD Tim Sparwasser, an associate of CRID and an influential researcher in the field of immunometabolism ⬇️⬇️⬇️

This study identifies AIM2 as a potential therapeutic target for psoriasis treatment, linking DNA sensing to inflammation in skin disease. #DermatologyResearch #AutoimmuneDiseases.

Mechanism Insights:. - AIM2 inflammasome activation required for psoriasis development.- Controls type 3 cytokine production (IL-17A, IL-23).- Regulates immune cell infiltration.- Creates feedback loop with IL-17A signaling.

Key findings:. - Elevated mitochondrial DNA levels in psoriasis patients.- High AIM2 expression in psoriatic epidermis.- AIM2 deletion reduces skin inflammation.- IL-17A induces AIM2 expression in keratinocytes #SkinResearch #Inflammation.

🔬 New research reveals how the DNA sensor AIM2 drives psoriasis by triggering type 3 immunity. Important findings from Timna Varela and team, under supervision of Jose Alves Filho in JCI insight.#Immunology #Psoriasis.

🎯 This discovery could lead to new pain treatments for viral infections! Funded by @fapesp #PainResearch #Science #Innovation.

🧪 "We showed that viral DNA recognition by STING participates in pain induction, directly activating neurons rather than through inflammation. This opens up new perspectives," explains Prof. Cunha, highlighting potential implications for viral infections, including COVID-19. 🔬.

📊 Key finding: Scientists identified that STING (an immune sensor) in pain neurons can detect viral DNA and trigger pain signals - independently of inflammation! Study used herpes virus (HSV-1) mouse models.